Amanda Anderson
About Amanda Anderson
Amanda Anderson is the Associate Director of Epidemiology, Hematology, and Cell Therapy at Bristol Myers Squibb in Greater Boston. She holds degrees from Smith College, University of Massachusetts, and Harvard School of Public Health, and has extensive experience in epidemiology and clinical research.
Title
Amanda Anderson serves as the Associate Director of Epidemiology, Hematology, and Cell Therapy at Bristol Myers Squibb in Greater Boston.
Education and Expertise
Amanda Anderson completed her Bachelor of Arts in Psychology and Neuroscience from Smith College from 2005 to 2009. She later pursued a Bachelor of Science in Nursing from the University of Massachusetts, Amherst, graduating in 2010. She further enhanced her academic qualifications by earning a Master's Degree in Epidemiology from the Harvard School of Public Health in 2016.
Professional Background
Amanda began her career at Massachusetts General Hospital, where she worked from 2010 to 2014 as a Clinical Research Nurse/Coordinator in Electrophysiology and Heart Failure Departments and as a Clinical Research Nurse in Cardiology and Heart Failure Departments. She then served as a Data Curator and Research Associate at Beth Israel Deaconess Medical Center and Massachusetts General Hospital from 2015 to 2016. Amanda later joined IQVIA, progressing from Consultant (2016-2018) to Senior Consultant (2018-2020) and then to Associate Principal in Epidemiology & Drug Safety (2020-2021).
Current Role at Bristol Myers Squibb
In her role at Bristol Myers Squibb, Amanda Anderson has made significant contributions. She received the 'Excellence in Epidemiology Research' award in 2022 and presented her findings at the 2022 American Society of Hematology Annual Meeting. She also mentors junior epidemiologists and clinical researchers, fostering the next generation of experts in her field.
Notable Achievements
Amanda has a distinguished record of accomplishments, including publishing a research paper on drug safety in a leading medical journal in 2020. While at IQVIA, she led a cross-functional team to develop a new data analysis framework for drug safety studies. Her work has been recognized with prestigious awards and presentations at key industry conferences.